Simon Chowdhury

25.5k total citations · 3 hit papers
199 papers, 5.1k citations indexed

About

Simon Chowdhury is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Simon Chowdhury has authored 199 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Pulmonary and Respiratory Medicine, 76 papers in Oncology and 69 papers in Cancer Research. Recurrent topics in Simon Chowdhury's work include Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (61 papers) and Cancer, Lipids, and Metabolism (38 papers). Simon Chowdhury is often cited by papers focused on Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (61 papers) and Cancer, Lipids, and Metabolism (38 papers). Simon Chowdhury collaborates with scholars based in United Kingdom, United States and Germany. Simon Chowdhury's co-authors include Margaret K. Yu, Angela Lopez‐Gitlitz, Axel S. Merseburger, Stéphane Oudard, Fred Saad, Boris Hadaschik, Kim N., Ke Zhang, Anders Bjartell and Paul N. Mainwaring and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Simon Chowdhury

191 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

2019 891 citations Kim N., Neeraj Agarwal et al. profile →
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

2018 868 citations Matthew R. Smith, Fred Saad et al. profile →
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

2021 285 citations Kim N., Simon Chowdhury et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Simon Chowdhury

Since Specialization

Citations

This map shows the geographic impact of Simon Chowdhury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Chowdhury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Chowdhury more than expected).

Fields of papers citing papers by Simon Chowdhury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Chowdhury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Chowdhury. The network helps show where Simon Chowdhury may publish in the future.

Co-authorship network of co-authors of Simon Chowdhury

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Chowdhury. A scholar is included among the top collaborators of Simon Chowdhury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Chowdhury. Simon Chowdhury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety. 2025 ·Journal of Clinical Oncology ·Alan H. Bryce, Ray McDermott, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Joel Roger Gingerich, Elias Pintus, Srikala S. Sridhar, Richard Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, (unknown), Wassim Abida, (unknown), Darrin Despain, Charles J. Ryan, Karim Fizazi, Simon Chowdhury	3
2	A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia 2024 ·Asia-Pacific Journal of Clinical Oncology ·Gavin Marx, Simon Chowdhury, Laurence E. Krieger, Elizabeth Hovey, Jeremy Shapiro, Ben Tran, Thean Hsiang Tan, Siobhan Ng, Henry H. Woo	0
3	Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney, (unknown)	3
4	Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy 2024 ·British Journal of Urology ·Axel S. Merseburger, (unknown), Anders Bjartell, Hirotsugu Uemura, Álvaro Juárez Soto, Amitabha Bhaumik, Jürgen Böhm, Nguyen Toan Tran, (unknown), (unknown), Suneel Mundle, Sabine Brookman‐May, Angela Lopez‐Gitlitz, Sharon McCarthy, Kim Chi, Simon Chowdhury	8
5	Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews 2023 ·Frontiers in Oncology ·Darren Leaning, Gagandeep Kaur, Alicia K. Morgans, (unknown), (unknown), Simon Chowdhury	8
6	Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study 2023 ·European Journal of Cancer ·Axel S. Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, (unknown), Andrea Juliana Gomes, Álvaro Juárez Soto, Robert Given, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Hirotsugu Uemura, Simon Chowdhury, Kim N., Anders Bjartell	14
7	Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells 2023 ·Cancer Medicine ·Sewanti Limaye, Simon Chowdhury, (unknown), Anantbhushan Ranade, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stefan Schuster, (unknown), Ajay Srinivasan, (unknown)	12
8	Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial 2023 ·Asian Journal of Andrology ·Byung Ha Chung, Jian Huang, Hiroji Uemura, Young Deuk Choi, Zhangqun Ye, Hiroyoshi Suzuki, Taek Won Kang, Dalin He, Jae Young Joung, Sabine Brookman‐May, Sharon McCarthy, Amitabha Bhaumik, (unknown), Suneel Mundle, Simon Chowdhury, Neeraj Agarwal, Dingwei Ye, Kim N., Hirotsugu Uemura	3
9	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer 2022 ·SHILAP Revista de lepidopterología ·Brian Labadie, David Morris, Alan H. Bryce, Robert Given, Jingsong Zhang, Wassim Abida, Simon Chowdhury, Akash Patnaik	4
10	A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer 2022 ·Future Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Simon Chowdhury, Bradley A. McGregor, Axel S. Merseburger, Stéphane Oudard, Fred Saad, Andrey Soares, Fawzi Benzaghou, Yannick Kerloëguen, Akiko Kimura, Nehal Mohamed, Ashok Panneerselvam, Fong Wang, Sumanta K. Pal	26
11	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease 2021 ·Clinical Cancer Research ·Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah Ricci, Brendan Rooney, Angela Lopez‐Gitlitz, Margaret K. Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small	9
12	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study breakdown → 2021 ·Journal of Clinical Oncology ·Kim N., Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Julie S. Larsen, Weili Sun, Katherine B. Bevans, Ke Zhang, Nibedita Bandyopadhyay, Neeraj Agarwal	285
13	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial 2019 ·Bladder Cancer ·Alexandra Drakaki, (unknown), Michiel S. van der Heijden, Daniel P. Petrylak, Thomas Powles, Kim N., Aude Fléchon, Andrea Necchi, Lajos Géczi, Jae‐Lyun Lee, Georgios Gakis, Sergio Bracarda, Simon Chowdhury, Chia‐Chi Lin, Daniel Keizman, Ulka N. Vaishampayan, Annamaria H. Zimmermann, Katherine M. Bell‐McGuinn, Daniel Castellano	2
14	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe 2017 ·European Urology ·Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliott, Enrique Grande, Amal Melhem‐Bertrandt, Benoît Baron, Mohammad Hirmand, Patrick Werbrouck, Karim Fizazi	80
15	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer 2017 ·Journal of Clinical Oncology ·Thomas Powles, Robert Huddart, Tony Elliott, (unknown), Charlotte Ackerman, Robert J. Jones, Syed A. Hussain, Simon J. Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, Graham Macdonald, Santhanam Sundar, J. Frew, Andrew Stockdale, Simon Hughes, Daniel M. Berney, Simon Chowdhury	142
16	Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested? 2016 ·BMJ Open ·Paul Nderitu, Mieke Van Hemelrijck, Mark Ashworth, Rohini Mathur, Sally Hull, (unknown), Simon Chowdhury	18
17	New developments in metastatic prostate cancer therapy. 2015 ·PubMed ·(unknown), Clare Gilson, Simon Chowdhury, Roger Kirby	1
18	The role of metastasectomy in renal cell carcinoma 2013 ·Expert Review of Anticancer Therapy ·(unknown), Alejo Rodríguez‐Vida, Myria Galazi, Simon Chowdhury, Aneta Suder	4
19	Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer 2011 ·Clinical Cancer Research ·Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter J. Ell, Andrew R. Reynolds, Thomas Powles	84
20	Recent advances in the use of aromatase inhibitors for women postmenopausal breast cancer 2005 ·The Journal of the British Menopause Society ·Simon Chowdhury, Peter Ellis	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact